Department of Neurosurgery and F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.
Department of Neurosurgery, Harvard Medical School, Boston, MA, USA.
Methods Mol Biol. 2025;2858:291-312. doi: 10.1007/978-1-0716-4140-8_22.
Glaucoma is marked by a progressive degeneration of the optic nerve and delayed loss of retinal ganglion cells (RGCs), the projection neurons of the eye. Because RGCs are not replaced and because surviving RGCs cannot regenerate their axons, the visual loss in glaucoma is largely irreversible. Here we describe methods to evaluate treatments that may be beneficial for treating glaucoma using in vitro cell culture models (immunopanning to isolate neonatal RGCs, dissociated mature retinal neurons, retinal explants) and in vivo models that test potential treatments or investigate underlying molecular mechanisms in an intact system. Potentially, the use of these models can help investigators continue to improve treatments to preserve RGCs and restore visual function in patients with glaucoma.
青光眼的特征是视神经进行性退化和视网膜神经节细胞(RGC)延迟丧失,RGC 是眼睛的投射神经元。由于 RGC 不能被替代,而且存活的 RGC 不能再生其轴突,因此青光眼的视力丧失在很大程度上是不可逆转的。在这里,我们描述了使用体外细胞培养模型(免疫选择分离新生 RGC、分离成熟的视网膜神经元、视网膜外植体)和体内模型评估可能有益于治疗青光眼的治疗方法的方法,这些模型可以帮助研究人员继续改进治疗方法,以保留 RGC 并恢复青光眼患者的视觉功能。